Following our long-standing interest in anti-lymphoma agents, coupled with the need for isoform-selective sirtuin modulators, we launched a medicinal chemistry effort to identify SIRT2 selective cambinol analogs and evaluate cytotoxicity against B-cell lymphomas. Here, SIRT2 is linked to B-cell non-Hodgkin lymphoma.